Visit https://www.peervoice.com/PBV860 to view the entire programme with slides. After completing “Nils Erik Gilhus, MD, PhD - Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Therapy in Generalised Myasthenia Gravis”, participants will be able to: Describe the role of autoantibodies in the pathophysiology of generalised myasthenia gravis (gMG); Identify the specific autoantibodies associated with gMG and the effects they have on the neuromuscular junction (NMJ); Explain why identifying autoantibody specificity is important for optimising clinical outcomes in patients with gMG; and Use the serological autoantibody status of patients with gMG to determine which therapeutic class is most appropriate for optimising clinical outcomes.

Nils Erik Gilhus, MD, PhD - Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Therapy in Generalised Myasthenia Gravis

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

Education

Training

Language Courses

Higher Education

K-12

Educational Technology

Medicine

Science & Medicine

Science

Health & Fitness

How To

Visit https://www.peervoice.com/ZHK860 to view the entire programme with slides. After completing “Jeffrey Szer, MBBS, FRACP - The Quest for Optimal Haemolytic Control of Paroxysmal Nocturnal Haemoglobinuria”, participants will be able to: Discuss the benefits and limitations of C5 inhibitors in the treatment of paroxysmal nocturnal haemoglobinuria (PNH); Differentiate between breakthrough haemolysis (BTH) and extravascular haemolysis (EVH) in patients who are receiving a terminal complement inhibitor; Evaluate clinically significant EVH in patients with PNH based on signs and symptoms; and Discuss key data on proximal complement inhibitors for the treatment of PNH and their role in clinical practice.

Jeffrey Szer, MBBS, FRACP - The Quest for Optimal Haemolytic Control of Paroxysmal Nocturnal Haemoglobinuria

Visit https://www.peervoice.com/RAS860 to view the entire programme with slides. After completing “Dirk Arnold, MD - Navigating Decisions With Limited Tools: A Review of Best Practices in Managing Metastatic Colorectal Cancer”, participants will be able to: Identify non-invasive molecular testing approaches to identify biomarkers of interest in patients with metastatic colorectal cancer (mCRC); Formulate individualised first-line treatment plans for patients with mCRC, based on factors such as molecular status and primary tumour location; and Assess the clinical relevance of clinical trial data evaluating novel combination therapies for the management of mCRC.

Dirk Arnold, MD - Navigating Decisions With Limited Tools: A Review of Best Practices in Managing Metastatic Colorectal Cancer

Visit https://www.peervoice.com/YZV860 to view the entire programme with slides. After completing “Lisa Licitra, MD - Are You Forearmed When Managing Toxicities Associated With Chemoradiotherapy in Patients With SCCHN?”, participants will be able to: Identify risk factors associated with toxicity development in patients with squamous cell carcinoma of the head and neck (SCCHN) who are undergoing chemoradiotherapy (CRT); Use patient and disease characteristics to determine pre-emptive approaches to reducing toxicity risk in patients with SCCHN who are to receive CRT; and Apply current recommendations for the management of CRT-associated toxicities in patients with SCCHN.

Lisa Licitra, MD - Are You Forearmed When Managing Toxicities Associated With Chemoradiotherapy in Patients With SCCHN?

Visit https://www.peervoice.com/QKR860 to view the entire programme with slides. After completing “Fatos Pinar Topsever, MD / Jennifer Green, MD - CGA - Identify and Intervene: Optimising Care Pathways for Chronic Kidney Disease in Patients With Type 2 Diabetes”, participants will be able to: Use recommended screening tests to identify chronic kidney disease (CKD) in patients with type 2 diabetes mellitus (T2DM); Evaluate current efficacy and safety evidence guiding the use of novel treatments for CKD in T2DM; and Apply best practices for the initiation and management of novel therapies for treatment of CKD and T2DM.

Fatos Pinar Topsever, MD / Jennifer Green, MD - CGA - Identify and Intervene: Optimising Care Pathways for Chronic Kidney Disease in Patients With Type 2 Diabetes

Visit https://www.peervoice.com/HPP860 to view the entire programme with slides. After completing “Jonathan W. Goldman, MD - Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC”, participants will be able to: Differentiate between pathophysiology of MET alterations in patients with NSCLC and the recommended strategies for their detection; Apply best practices to overcome challenges in the identification of patients with NSCLC and MET vulnerabilities; and Summarize current and emerging strategies for targeting MET alterations as a therapeutic vulnerability in patients with NSCLC.

Nils Erik Gilhus, MD, PhD - Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Therapy in Generalised Myasthenia Gravis

Download our free app to listen on your phone